Drug Trial Radar · NCT01677182
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
Last checked: Nov 20, 2026Latest source record: Mar 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
535
Actual
Start
Aug 2012
Primary completion
Aug 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Aug 31, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of ramelteon for treatment of acute depressive episodes associated with Bipolar 1 Disorder.
Conditions
- Bipolar Disorder
Interventions
RamelteonDrug
Ramelteon tablets for sublingual administration
PlaceboDrug
Ramelteon placebo-matching tablets for sublingual administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6Time frame: Baseline and Week 6
Locations
104 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Anaheim, California
Site not named
Glendale, California
Site not named
Imperial, California
Site not named
Los Angeles, California
Site not named
Oakland, California
Site not named
Oceanside, California
Site not named
Pico Rivera, California
Site not named
San Diego, California
Site not named
Stanford, California
Site not named
Hartford, Connecticut
Site not named
Coral Springs, Florida
Site not named
Deerfield Beach, Florida
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Maitland, Florida
Site not named
Oakland Park, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
West Palm Beach, Florida
Site not named
Chicago, Illinois
Site not named
Joliet, Illinois
Site not named
Naperville, Illinois
Site not named
Oak Brook, Illinois
Site not named
Lafayette, Indiana
Site not named
Boston, Massachusetts
Site not named
St Louis, Missouri
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Staten Island, New York
Site not named
The Bronx, New York
Site not named
Avon Lake, Ohio
Site not named
Cincinnati, Ohio
Site not named
Garfield Heights, Ohio
Site not named
Mason, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Memphis, Tennessee
Site not named
San Antonio, Texas
Site not named
Bothell, Washington
Site not named
Spokane, Washington
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.